Mictonorm Uno (Propiverine Hydrochloride)

Mictonorm Uno, an antimuscarinic agent that relaxes the detrusor muscle, is employed to manage several symptoms associated with overactive bladder activity.

• Overactive bladder: reduces urinary urgency and frequency by decreasing involuntary detrusor contractions, improving bladder storage capacity.
• Urgency urinary incontinence: lessens episodes of sudden urge to void that lead to involuntary leakage, enhancing continence control.
• Frequency: decreases the number of daytime voids, helping patients achieve a more normal voiding pattern.

• Propiverine Hydrochloride acts as a competitive antagonist at muscarinic acetylcholine receptors (M2 and M3 subtypes) located on the detrusor smooth muscle of the urinary bladder. By blocking these receptors, it inhibits acetylcholine‑mediated contractions, leading to relaxation of the bladder wall and a reduction in involuntary contractions. This pharmacological effect improves bladder storage capacity and diminishes symptoms of urgency, frequency, and urge incontinence.

Propiverine Hydrochloride may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Dry mouth: reduced salivary secretion causing thirst and discomfort.
• Constipation: slowed gastrointestinal motility resulting in hard stools.
• Blurred vision: transient visual disturbances due to ocular anticholinergic effect.
• Headache: mild to moderate head pain often resolving without intervention.

Serious or Rare Side Effects

• Urinary retention: difficulty emptying the bladder that may require catheterisation.
• Severe allergic reaction (anaphylaxis): rash, swelling, breathing difficulty demanding immediate medical care.
• Angle‑closure glaucoma: sudden eye pain and visual loss, a medical emergency.

When prescribing Propiverine Hydrochloride, clinicians should consider several precautionary measures to ensure safe use.

• Assess renal function: evaluate kidney performance and consider dose adjustment or alternative therapy in patients with moderate to severe renal impairment.
• Monitor for urinary retention: observe for signs of incomplete bladder emptying, especially during the first weeks of therapy, and intervene if necessary.
• Avoid in narrow‑angle glaucoma: anticholinergic action may raise intra‑ocular pressure.
• Use cautiously in the elderly: older adults may experience heightened anticholinergic adverse effects such as confusion, dry mouth, and constipation.
• Store at room temperature: keep in original container, protect from moisture and sunlight.

Propiverine Hydrochloride can interact with other medicines; recognizing the level of interaction helps guide safe co‑administration.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase propiverine plasma concentrations.
• Concurrent anticholinergic drugs (e.g., oxybutynin, tolterodine): additive anticholinergic burden can exacerbate side effects.
• P‑glycoprotein inhibitors (e.g., verapamil): may reduce drug efflux and raise systemic exposure.

Moderate Interactions (Monitor Closely)

• Diuretics: may alter bladder volume and affect symptom assessment.
• Beta‑3 adrenergic agonists (e.g., mirabegron): combined effect on bladder may increase risk of urinary retention.
• Antihistamines with anticholinergic properties: may enhance dry mouth and constipation.